Cross Road Biotech

CRB bio II Fund Launched to Invest in Early Stage Biotech in Spain. The Fund will be managed by a new VC Firm CRB Inverbío a Spanish company with wide experience and track record in bio investments. Now raising with an expected final closing at 60M euros. Please contact comunicacion@crossroadbiotech.com for more details CRB is a Spanish Private Equity company founded in 2004 that invests in innovative, high potential biotech start ups in early phases. CRB´s mission is to fill the gap between science and industry and is engaged in the task of transforming bio-medic research projects into profitable businesses. CRB has clear competitive advantages: •Experienced, multifunctional management team •Access to the scientific sources and inter-communication capability with the scientific teams •Willingness to invest in early development phases •When feasible, taking a controlling equity position in the company •Specialization •Hands on involvement in the portfolio companies: •Ability to raise non-diluting public financing •Few “off limits” and investment restrictions CRB has a diversified portfolio in relevant therapeutic and diagnostic areas of global impact like Cancer, Alzheimer, Liver diseases, VIH etc…. CRB also wants to increase the visibility of the projects in the current portfolio and explore new alliances and collaborations. CRB projects have global relevance hence wants to develop long range relationships with stakeholders in the pharma/biotech industry